DANIEL J. WALLACE, M.D.; KIM MARGOLIN, M.D.; PAM WALLER, R.N.
To the editor: We read with interest the study by Denicoff and colleagues (1) on the neuropsychiatric effects of treatment with interleukin-2 with or without lymphokine-activated killer cells. The authors observed that most patients had decreased energy, fatigue, anorexia, malaise, and sleep disturbances. In neither this report nor the group's most recent toxicity survey is there any mention of musculoskeletal complications, even though such symptoms were briefly discussed previously (2, 3). The City of Hope National Medical Center is one of six collaborating centers using variations of the Rosenberg protocol. Many of the patients we have treated were observed to
DANIEL J. WALLACE, KIM MARGOLIN, PAM WALLER. Fibromyalgia and Interleukin-2 Therapy for Malignancy. Ann Intern Med. 1988;108:909. doi: 10.7326/0003-4819-108-6-909_1
Download citation file:
Published: Ann Intern Med. 1988;108(6):909.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use